3.75

1.49% 0.05

Macrogenics Inc (MGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Macrogenics Inc stock is traded at $3.75, with a volume of 137.30K. It is up +1.49% in the last 24 hours and up +4.60% over the past month. Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Previous Close:

$3.70

Open:

$3.7

24h Volume:

137.30K

Relative Volume:

0.22

Market Cap:

$232.39M

Revenue:

$56.91M

Net Income/Loss:

$-9.06M

P/E Ratio:

31.25

EPS:

0.12

Net Cash Flow:

$-79.97M

1W Performance:

+12.43%

1M Performance:

+4.60%

6M Performance:

-76.04%

1Y Performance:

-29.28%

1-Day Range:

$3.65

$3.765

1-Week Range:

$3.211

$3.95

52-Week Range:

$2.9511

$21.88

Macrogenics Inc Stock (MGNX) Company Profile

Name

Macrogenics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

301-251-5172

Address

9704 MEDICAL CENTER DRIVE, Rockville, MD

Employee

339

Twitter

@macrogenics

Next Earnings Date

2024-11-05

Latest SEC Filings

MGNX's Discussions on Twitter

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-23	Upgrade	Citigroup	Neutral → Buy
Nov-07-23	Upgrade	Guggenheim	Neutral → Buy
Mar-17-23	Downgrade	Guggenheim	Buy → Neutral
Nov-22-22	Downgrade	Cowen	Outperform → Market Perform
Nov-14-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jul-18-22	Downgrade	SMBC Nikko	Outperform → Neutral
Jul-11-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
May-04-22	Downgrade	Guggenheim	Buy → Neutral
Feb-28-22	Upgrade	Citigroup	Neutral → Buy
Feb-11-22	Initiated	BMO Capital Markets	Outperform
Feb-04-22	Initiated	SMBC Nikko	Outperform
Nov-17-21	Resumed	Guggenheim	Buy
Oct-19-21	Initiated	JMP Securities	Mkt Outperform
Oct-15-21	Resumed	BTIG Research	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-12-21	Upgrade	Barclays	Underweight → Overweight
Dec-22-20	Resumed	H.C. Wainwright	Buy
Aug-03-20	Downgrade	Citigroup	Buy → Neutral
Jun-01-20	Upgrade	Guggenheim	Neutral → Buy
May-26-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Underweight
Dec-19-19	Initiated	Cantor Fitzgerald	Overweight
Dec-18-19	Initiated	Cantor Fitzgerald	Overweight
Nov-21-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-20-19	Resumed	Guggenheim	Neutral
May-03-19	Upgrade	Wedbush	Neutral → Outperform
Apr-12-19	Initiated	Guggenheim	Neutral
Feb-07-19	Upgrade	Citigroup	Sell → Buy
Feb-07-19	Downgrade	Wedbush	Outperform → Neutral
Feb-06-19	Upgrade	Raymond James	Underperform → Mkt Perform
Feb-04-19	Downgrade	Citigroup	Neutral → Sell
Dec-10-18	Downgrade	Raymond James	Outperform → Underperform
Sep-10-18	Resumed	BTIG Research	Buy
May-31-18	Initiated	Evercore ISI	Outperform
Mar-05-18	Initiated	H.C. Wainwright	Buy
Mar-31-17	Initiated	Raymond James	Outperform

View All

Macrogenics Inc Stock (MGNX) Latest News

Nov 04, 2024

Macrogenics Earnings Preview - Benzinga

Nov 04, 2024

Earnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 Result - GuruFocus.com

Nov 04, 2024

Nov 02, 2024

MacroGenics CEO Scott Koenig to resign early next year By Investing.com - Investing.com UK

Oct 30, 2024

Oct 29, 2024

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call - GlobeNewswire

Oct 29, 2024

Oct 26, 2024

MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from Analysts - MarketBeat

Oct 26, 2024

Oct 25, 2024

MacroGenics (NASDAQ:MGNX) Stock Rating Upgraded by StockNews.com - MarketBeat

Oct 25, 2024

Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders - StockTitan

Oct 25, 2024

MacroGenics' SWOT analysis: stock faces challenges amid pipeline setbacks - Investing.com India

Oct 25, 2024

Oct 23, 2024

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and MaplebearJohnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire

Oct 23, 2024

Oct 22, 2024

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA - citybiz

Oct 22, 2024

MGNXMacroGenics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 22, 2024

MacroGenics sells breast cancer treatment to TerSera - The Business Journals

Oct 22, 2024

TerSera acquires rights to MacroGenics cancer drug MARGENZA - Investing.com

Oct 22, 2024

MacroGenics to Sell Margenza Cancer Drug for $40 Million - MarketWatch

Oct 22, 2024

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA® - Business Wire

Oct 22, 2024

Oct 21, 2024

TerSera Therapeutics LLC has entered into an agreement to acquire MARGENZA® from MacroGenics, Inc. for $75 million. - Marketscreener.com

Oct 21, 2024

Oct 16, 2024

Prepare Yourself for Liftoff: Macrogenics Inc (MGNX) - SETE News

Oct 16, 2024

Investor’s Delight: Macrogenics Inc (MGNX) Closes Weak at 3.98, Down -7.01 - The Dwinnex

Oct 16, 2024

Oct 15, 2024

What was Macrogenics Inc (MGNX)’s performance in the last session? - US Post News

Oct 15, 2024

Oct 14, 2024

The MGNX Stock Puzzle: Unraveling Macrogenics Inc’s Fluctuating Performance - The InvestChronicle

Oct 14, 2024

Oct 11, 2024

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, - EIN News

Oct 11, 2024

Examining Macrogenics Inc (MGNX) stock is warranted - US Post News

Oct 11, 2024

Oct 10, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc.MGNX - cnhinews.com

Oct 10, 2024

Dimensional Fund Advisors LP Reduces Stock Position in MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat

Oct 10, 2024

Oct 07, 2024

Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight - GlobeNewswire Inc.

Oct 07, 2024

Millennium Management LLC Boosts Stock Position in MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat

Oct 07, 2024

Oct 04, 2024

MacroGenics, Inc. (NASDAQ:MGNX) Position Increased by Marshall Wace LLP - MarketBeat

Oct 04, 2024

Oct 03, 2024